May. 4 at 2:02 AM
$VSTM reports Q126 sales of its LGSOC combo Thursday after the close
For its 1st 2 full fiscal quarters post launch, sales of VSTM's combo therapy have tracked sales of CTIC's Vonjo & are handily higher than ZGNX's Fintepla. Both
$CTIC &
$ZGNX were acquired for enterprise values of
$1.7B. If you believe actual product sales are a barometer, again a barometer, for valuation potential then investors should follow VSTM.
If VSTM's Q126 sales are on par or beat analyst estimates then it may affirm VSTM's LGSOC hypothetical M&A exit valuation could be on par with CTIC & ZGNX. Just remember VSTM fully diluted shares are roughly 20% higher.
We'll add a comparison to
$DAWN Ojemda sales (VSTM running roughly 1/3 less but DAWN exited at ~
$2.2B ish). The dots connect
VSTM has a 2nd asset showing genuine promise in solid tumors with a KRAS 12D mutation (very roughly 15% of all solid tumors, higher in some & lower in others). Updated data is due in Q226.
This is not investment advice.
$XBI
